Tecentriq + chemo increase OS, PFS in untreated extensive stage small cell lung cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Genentech said that the phase III IMpower133 study met its co-primary endpoints of overall survival and progression-free survival at its first interim analysis.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Confidential Trump administration budget documents show that the upcoming FY26 Budget Request will radically cut about $50 billion out of the U.S. Department of Health and Human Services, reshuffling agency components, and slashing the number of NIH institutes and centers to just eight. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login